Plain-English reading on the vagus nerve, its science and how to look after it
How It Works

What Neurotransmitter Does the Vagus Nerve Release?

A flat folk-art illustration of a nerve ending holding tiny round neurotransmitter vesicles, with clusters of wild roses and buttercups tucked along its outline.

The vagus nerve releases acetylcholine as its primary neurotransmitter. This single fact, however, understates the complexity of vagal neurotransmission. The vagus nerve uses acetylcholine to slow the heart, stimulate digestion, and suppress inflammation, but the receptors it targets, the co-transmitters it releases alongside acetylcholine, and the signalling it carries in the afferent direction all tell a richer story. This article explains what happens at the molecular level when the vagus nerve fires.

Acetylcholine: The Primary Vagal Neurotransmitter

Acetylcholine (ACh) is released by efferent (motor) vagal fibres at their target organs. It is synthesised from choline and acetyl-CoA by the enzyme choline acetyltransferase and stored in synaptic vesicles at nerve terminals. When an action potential reaches the terminal, calcium influx triggers vesicle fusion and ACh release into the synaptic cleft.

The effects of vagally released acetylcholine depend entirely on which receptors it binds. There are two major families of acetylcholine receptors, and the vagus nerve engages both.

A flat folk-art vector illustration of a human nerve cell encircled by wild roses, buttercups and grasses.

Muscarinic Receptors: Heart, Gut, and Glands

Muscarinic receptors (named after muscarine, a mushroom toxin) are G-protein-coupled receptors found on the target organs of postganglionic vagal fibres. Five subtypes exist (M1 through M5), but three are most relevant to vagal function.

M2 receptors are the dominant subtype in the heart. When acetylcholine binds M2 receptors on sinoatrial node cells, it activates an inhibitory G-protein that opens inward-rectifier potassium channels (GIRK/Kir3 channels). The resulting potassium efflux hyperpolarises the cell, slowing spontaneous depolarisation and reducing heart rate. This is the direct mechanism of vagal cardiac braking, and it is why atropine (a muscarinic antagonist) blocks vagal slowing of the heart.

M3 receptors are found in smooth muscle of the gastrointestinal tract, airways, and blood vessels, and in glandular tissue. Vagal acetylcholine acting on M3 receptors stimulates gut motility, increases secretion of digestive enzymes and gastric acid, and promotes bronchial smooth muscle contraction. M1 receptors contribute to gastric acid secretion through enteric neurons.

The specificity of these receptor subtypes is clinically important. Medications targeting specific muscarinic subtypes can modulate one vagal effect without disrupting others. For example, pirenzepine (M1 selective) reduces gastric acid secretion without significantly affecting heart rate.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Nicotinic Receptors: Ganglia and Inflammation

Nicotinic receptors (named after nicotine) are ligand-gated ion channels. In the context of vagal neurotransmission, they serve two distinct roles.

First, at the parasympathetic ganglia, preganglionic vagal fibres release acetylcholine onto nicotinic receptors on postganglionic neurons. This is the relay point: the signal from the brainstem is transmitted to the local neurons that innervate the target organ. The nicotinic receptors here are of the neuronal subtype (primarily containing alpha-3 and beta-4 subunits).

Second, and more recently discovered, nicotinic receptors play a central role in the cholinergic anti-inflammatory pathway. Kevin Tracey and colleagues identified this pathway in 2000, demonstrating that vagus nerve stimulation could suppress systemic inflammation through acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (alpha-7 nAChR) on macrophages and other immune cells. When acetylcholine binds alpha-7 nAChR on macrophages, it inhibits the release of pro-inflammatory cytokines including TNF-alpha, IL-1-beta, and IL-6, without affecting anti-inflammatory cytokines like IL-10.

A sculpted matte clay nerve ending releasing neurotransmitter molecules, with one bright golden light element.

The Cholinergic Anti-Inflammatory Pathway

The cholinergic anti-inflammatory pathway is one of the most important discoveries in vagus nerve science. It provides a direct neural mechanism for regulating immune function and has reshaped understanding of how the nervous system interacts with the immune system.

The pathway involves vagal efferent fibres projecting to the coeliac ganglion, from which the splenic nerve carries signals to the spleen. In the spleen, a specialised population of T cells releases acetylcholine (these T cells express choline acetyltransferase), which then acts on alpha-7 nAChR on splenic macrophages. This relay mechanism, in which T cells rather than nerve endings provide the final acetylcholine signal, was unexpected and revealed a previously unknown neuroimmune circuit.

The clinical significance is substantial. SetPoint Medical has developed a bioelectronic medicine approach based on this pathway, using implanted vagus nerve stimulation to treat rheumatoid arthritis. Their device targets the inflammatory reflex, and clinical trial data have shown reductions in disease activity scores in patients with treatment-resistant RA. The FDA granted Breakthrough Device designation for this approach.

Research published in Frontiers in Neuroscience in 2024 reviewed the current state of cholinergic anti-inflammatory pathway targeting, noting that alpha-7 nAChR agonists, vagus nerve stimulation, and non-invasive auricular stimulation are all being investigated as ways to harness this pathway for inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, and sepsis.

Co-Transmitters and Neuropeptides

Acetylcholine is not the only signalling molecule released by vagal nerve terminals. Vagal efferent fibres co-release several neuropeptides alongside acetylcholine, including vasoactive intestinal peptide (VIP) and nitric oxide (NO).

VIP is a 28-amino acid peptide that acts as a co-transmitter in parasympathetic neurons innervating the gut, airways, and blood vessels. It promotes smooth muscle relaxation, vasodilation, and secretion. In the gut, VIP helps regulate motility and fluid secretion. In the airways, it acts as a bronchodilator. The interplay between acetylcholine (which contracts smooth muscle via M3 receptors) and VIP (which relaxes it) allows fine-tuned control of organ function.

Nitric oxide, synthesised by neuronal nitric oxide synthase (nNOS) in vagal nerve terminals, serves as a non-adrenergic, non-cholinergic (NANC) neurotransmitter in the gut. It mediates relaxation of the lower oesophageal sphincter, gastric accommodation (the stomach’s ability to expand to receive food), and descending relaxation during peristalsis. Impaired vagal NO signalling contributes to conditions such as achalasia (failure of the lower oesophageal sphincter to relax) and gastroparesis.

Afferent Vagal Signalling

Approximately 80 percent of vagal fibres are afferent (sensory), carrying information from the organs to the brain rather than the other way round. These afferent fibres do not release acetylcholine as their primary neurotransmitter. Instead, they use glutamate as the main excitatory neurotransmitter at their central synapses in the nucleus tractus solitarius (NTS) in the brainstem.

Vagal afferent fibres also contain and release various neuropeptides depending on their subtype, including substance P, calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), and glucagon-like peptide-1 (GLP-1). These peptides serve as neuromodulators, influencing the processing of visceral sensory information in the brainstem and contributing to functions such as satiety signalling, nausea, and pain.

The distinction between efferent and afferent vagal neurotransmitters matters because most of the therapeutic effects attributed to vagus nerve stimulation, whether through implanted devices or transcutaneous auricular stimulation, are now thought to work primarily through afferent pathways, activating brainstem circuits rather than directly releasing acetylcholine at peripheral organs.

Clinical Implications

Understanding vagal neurotransmitter pharmacology has direct clinical applications. Atropine blocks muscarinic receptors to counteract excessive vagal slowing of the heart. Prokinetic agents enhance cholinergic signalling in the gut to treat gastroparesis. Anticholinesterase drugs (which prevent acetylcholine breakdown) are used in myasthenia gravis and Alzheimer’s disease. Alpha-7 nAChR agonists are being developed for inflammatory and neurodegenerative conditions.

The answer to “what neurotransmitter does the vagus nerve release?” is acetylcholine, but the full picture includes the receptor subtypes it targets, the co-transmitters released alongside it, the anti-inflammatory pathway it mediates, and the entirely different neurotransmitter profile of the afferent fibres that make up most of the nerve. This complexity is what makes the vagus nerve such a versatile therapeutic target.

The neurotransmitter chemistry of the vagus nerve is just one layer of a fascinating system that connects your brain to virtually every organ. If you want to understand the full scope of vagal science, from molecular mechanisms to practical stimulation techniques, the My Vagus Nerve & Me eBook covers it all. Get My Vagus Nerve & Me eBook and discover how acetylcholine and the vagus nerve shape your health.

This article is for general information and is not medical advice. Talk to a qualified clinician before changing anything about your health or treatment. Read our medical disclaimer. Spotted an error? Let us know.